HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial

Lancet

Volumn 350, Issue 9083, 1997, Pages 983-990

  Brun Vézinet, Francoise ^a   Boucher, Charles ^b   Loveday, Clive ^c   Descamps, Diane ^a   Fauveau, Véronique ^d   Izopet, Jacques ^e   Jeffries, Don ^f   Kaye, Steve ^g   Krzyanowski, Corinne ^h   Nunn, Andrew ⁱ   Schuurman, Rob ^b   Seigneurin, Jean Marie ^j   Tamalet, Catherine ^k   Tedder, Richard ^g   Weber, Jonathan ^l   Weverling, Gerrit Jan ^m  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d HÔPITAL ROTHSCHILD   (France)

^e CHU PURPAN   (France)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h INSERM   (France)

ⁱ Med Res Cncl HIV Clin Trials C   (United Kingdom)

^j Hôpital Richallon   (France)

^k TIMONE HOSPITAL   (France)

^l ST MARY S HOSPITAL   (United Kingdom)

^m Windeyer Building ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; DIDANOSINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; MONONUCLEAR CELL; MULTICENTER STUDY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; VIRUS CULTURE;

EID: 0030764022     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)03380-1     Document Type: Article

References (23)

1. Delta coordinating committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91.
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996: 335: 1081-91.
3. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome and fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-106.
4. Rouzioux C, Puel J, Agut H, et al. Comparative assessment of quantitative HIV viraemia assays. AIDS 1992; 6: 373-77.
5. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994; 32: 732-39.
6. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32: 292-300.
7. Kaye S, Loveday C, Tedder RS. A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J Med Virol 1992; 37: 241-46.
8. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, Noordaa van der J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
9. Brun-Vézinet F, Ingrand D, Deforges L, et al. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods 1992; 37: 177-88.
10. Tersmette M, de Goede REY, Al BJM, et al. Differential syncytium-inducing capacity of HIV isolates: frequent detection of syncytium-inducing isolates in patients with AIDS and ARC. J Virol 1988; 62: 2026-32.
11. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
12. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 655-60.
13. Schuurman R, Descamps D, Weverling GJ, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34: 3016-22.
14. Mellors JW, Rinalde CR, Gupta P, White RM, Todd JA, Kinglsey LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
15. Zhang LQ, Simmonds P, Ludlam CA, Leigh-Brown AJ. Detection, quantification and sequencing of HIV-1 from, the plasma of seropositive individuals and factor VIII concentrates. AIDS 1991; 5: 675-81.
16. Boucher CA, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165: 105-10.
17. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay (LiPA) for the detection of drug-selected variants in the HIV-1 reverse transcriptase gene. Int Antiviral News 1997; 5: 38-40.
18. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-98.
19. Rey D, Pi T, Diehl LJ, Hughes M, Merigan TC, Katzenstein DA. Do plasma codon 215 mutations explain the failure of ZDV in ACTG 175? Fifth International Workshop on HIV drug resistance. Whistler 1996; 3-6 July: (abstr 38).
20. + cells per cubit millimeter. N Engl J Med 1995; 333: 1662-69.
21. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. JAMA 1996; 276: 118-25.
22. Schooley RT, Ramirez-Ronda C, Lange JMA, et al. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173: 1354-66.
23. Larder BA, Kohli A, Bloor S, et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxycytidine combination therapy. J Virol 1996; 70: 5922-29.